PCM
OCUL icon

Portolan Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Portolan Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-151,292
Closed -$1.42M – 129
2015
Q4 		$1.42M Sell
151,292
-340,933
-69% -$3.68M 0.18% 113
2015
Q3 		$6.92M Buy
492,225
+369,707
+302% +$7.43M 0.92% 43
2015
Q2 		$2.58M Buy
+122,518
New +$3.04M 0.36% 92

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Portolan Capital Management's OCUL Position: Q1 2016 in Review

Portolan Capital Management sold out of Ocular Therapeutix (OCUL) in Q1 2016, closing a stake of 151,292 shares — an estimated $1.42M sold.

Portolan Capital Management first reported a position in OCUL in Q2 2015 and held it in 3 quarters. The position peaked at $6.92M in Q3 2015. 64 funds tracked by Wall St. Rank hold OCUL as of Q1 2016.

  • Portolan Capital Management reported no remaining Ocular Therapeutix position as of Q1 2016 after selling out during the quarter.
  • Portolan Capital Management sold 151,292 Ocular Therapeutix shares in Q1 2016, an estimated $1.42M.
  • Portolan Capital Management first reported a position in Ocular Therapeutix in Q2 2015 and held it in 3 quarters.
  • Portolan Capital Management's Ocular Therapeutix position peaked at $6.92M in Q3 2015.
  • 64 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2016.

Based on Portolan Capital Management's 13F filing for Q1 2016, filed 13 May 2016.